Exchange: NYSE·Updated 09:27 PM EDT
News
all
press releases
Aging Population Drives Healthcare Growth: Stocks to Watch
AbbVie, Tandem Diabetes Care and Amgen are targeting aging-related healthcare growth through advances in immunology, diabetes and cardiovascular care.
Zacks
More News
Boston Scientific (BSX) Up 1.5% Since Last Earnings Report: Can It Continue?
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
New Strong Sell Stocks for August 28th
AU, APTV and BSX have been added to the Zacks Rank #5 (Strong Sell) List on August 28th, 2026.
Zacks
Intuitive Surgical's Record Cash Flow Gives It an Innovation Advantage
ISRG's record cash flow is fueling R&D, manufacturing expansion and over 100 da Vinci 5 updates, strengthening its innovation edge.
Zacks
Stock Market Today, Aug. 26: Boston Scientific Shares Fall 5% on Cybersecurity Incident and Product Recall
Boston Scientific (NYSE:BSX), a global medical device maker, closed at $48.17, down 3.38%. Premarket reports said a cybersecurity incident disrupted global operations and shipping. The company also announced a product recall for certain types of its percutaneous catheters, furthe...
Nasdaq News: Markets
Boston Scientific Reports Global Disruption After Cybersecurity Incident
Boston Scientific reports a cyber incident disrupting global operations, limiting system access and affecting order processing and shipments.read more...
Benzinga
Why Boston Scientific Stock Crashed Today
Key PointsBoston Scientific said its global operations were disrupted by a "cybersecurity incident...
Nasdaq News: Markets
MDT's Q1 Earnings on Deck: How Should You Play the Stock Now?
Medtronic's Q1 results may reflect strong growth across Cardiovascular, Neuroscience and Diabetes, but earnings beat signals remain mixed.
Zacks
Medical device maker Boston Scientific is being hit by a cyberattack. The shares are falling
The attack has disrupted the company's ability to ship products, and it's not clear when services will be restored...
CNBC: Top News
Is TFX a Buy Now as Valuation Improves but Execution Risks Remain?
Valuation is improving for Teleflex, but slower Vascular Intervention integration and margin pressure keep execution risks in focus.
Zacks

Advertisement|Remove ads.